Pharma BD Deal Intelligence

Amgen Inc. / Abgenix, Inc.

2005 · Acquisition/Merger · $2.2B · Complete

Announcement Sentiment

Strongly positive

Amgen agrees to acquire Abgenix for $22.50/share cash (~$2.2B) plus debt. Gains full ownership of panitumumab (Vectibix) + XenoMouse antibody platform; eliminates denosumab royalty.

Key facts

Announced Dec 14, 2005
Closed Apr 03, 2006
Deal value $2.2B
Deal type Acquisition/Merger

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals